Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor

International Journal of Gastrointestinal Cancer

Volumn 36, Issue 1, 2005, Pages 55-58

  Tetzlaff, Eric D ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinoid; Chromogranin A; Interferon alpha; Octreotide; Oxaliplatin

Indexed keywords

FLUOROURACIL; OCTREOTIDE; OXALIPLATIN;

ADULT; ANAMNESIS; ARTICLE; CARCINOID; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE COURSE; ESOPHAGOGASTRODUODENOSCOPY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MEDICAL EXAMINATION; NEEDLE BIOPSY; PRIORITY JOURNAL; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 26644431577     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:36:1:055     Document Type: Article

References (16)

1. Lubarsch O. Uber den primareren krebs des ileim nebst bemerkungen ueber das gleichzeitige vorkommen von krebs und tuberculos. Virchows Arch 1888;11:280-317.
2. Masson P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of appendicular mucosa. Am J Pathol 1928;4:181-212.
3. Maggard MA, O'connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117-122.
4. Schnirer I, Yao J, Ajani J. Carcinoid: a comprehensive review. Acta Oncol 2003;42(7):672-692.
5. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327-324.
6. Saltz L, Kemeny N, Schwartz G, et al. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994;74:958-961.
7. Pazdur R. Food and Drug Administration [FDA Website] January 9, 2004. Available at: http://www.fda.gov/cder/foi/appletter/2004/21492se1-0021tr.pdf. Accessed July 22, 2005.
8. Kweekwl D, Gelderblom H, Guchelaar H. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105.
9. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyramidnes. Annal Oncol 1996;7:95-98.
10. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69(4):893-900.
11. Chollet P, Bensmaine A, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Annal Oncol 1996;7:1065-1070.
12. Monnet I, Brienza S, Hugret F, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 1998;34:1124-1127.
13. Louvet C, Andre T, Tiagaud JM. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548.
14. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92(3):205-216.
15. Andre T, Corrado B, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 1004;350:2343-2351.
16. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment of metastatic colon cancer. J Clin Oncol 2000;18:2938-2947.